NCT06655740View on ClinicalTrials.gov

Safety, Tolerability, and Effectiveness of Duodenal Mucosal RF Vapor Ablation for Insulin Elimination in Type-2 Diabetes

NARecruitingINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

July 31, 2025

Conditions

Diabetes Mellitus, Type 2

Interventions

DEVICE

RF Vapor Ablation

RF Vapor ablation of the duodenum

Trial Locations (1)

Unknown

RECRUITING

Clinica Colonial, Santiago

Sponsors

Lead Sponsor

Aqua Medical, Inc.

All Listed Sponsors

lead

Aqua Medical, Inc.

INDUSTRY

NCT06655740 - Safety, Tolerability, and Effectiveness of Duodenal Mucosal RF Vapor Ablation for Insulin Elimination in Type-2 Diabetes | Biotech Hunter | Biotech Hunter